Φορτώνει......
The impact of discontinuation of sacubitril–valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction
OBJECTIVE: Many trials confirmed the role of sacubitril–valsartan in the treatment of patients with heart failure with reduced ejection fraction (HFrEF). However, there is no sufficient data to register the effect of compulsory discontinuation of sacubitril–valsartan, either because of financial sho...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Anatol J Cardiol |
|---|---|
| Κύριοι συγγραφείς: | , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Turkish Society of Cardiology
2021
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8114728/ https://ncbi.nlm.nih.gov/pubmed/33690130 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14744/AnatolJCardiol.2020.39267 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|